Search details
1.
Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies.
CA Cancer J Clin
; 72(2): 165-182, 2022 03.
Article
in English
| MEDLINE | ID: mdl-34767258
2.
Enhancing global access to cancer medicines.
CA Cancer J Clin
; 70(2): 105-124, 2020 03.
Article
in English
| MEDLINE | ID: mdl-32068901
3.
Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement.
CA Cancer J Clin
; 70(6): 480-504, 2020 11.
Article
in English
| MEDLINE | ID: mdl-32910493
4.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
N Engl J Med
; 386(12): 1143-1154, 2022 03 24.
Article
in English
| MEDLINE | ID: mdl-35320644
5.
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
Lancet Oncol
; 2024 May 03.
Article
in English
| MEDLINE | ID: mdl-38710187
6.
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations.
Lancet Oncol
; 25(2): e73-e83, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38301705
7.
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study.
Cancer
; 2024 May 16.
Article
in English
| MEDLINE | ID: mdl-38752572
8.
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
Lancet
; 401(10371): 105-117, 2023 01 14.
Article
in English
| MEDLINE | ID: mdl-36495879
9.
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience.
Oncologist
; 29(2): 159-165, 2024 Feb 02.
Article
in English
| MEDLINE | ID: mdl-37669224
10.
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis.
Oncologist
; 2024 May 08.
Article
in English
| MEDLINE | ID: mdl-38716772
11.
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology.
Oncologist
; 2024 Mar 23.
Article
in English
| MEDLINE | ID: mdl-38520742
12.
Immune-Related Adverse Event Likelihood Score Identifies "Pure" IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population.
Oncologist
; 29(2): e266-e274, 2024 Feb 02.
Article
in English
| MEDLINE | ID: mdl-37715957
13.
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents.
Oncologist
; 29(1): 75-83, 2024 Jan 05.
Article
in English
| MEDLINE | ID: mdl-37548439
14.
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
Oncologist
; 29(4): 303-310, 2024 Apr 04.
Article
in English
| MEDLINE | ID: mdl-37995313
15.
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study.
Future Oncol
; 20(6): 297-306, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37916501
16.
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
JAMA
; 331(13): 1135-1144, 2024 04 02.
Article
in English
| MEDLINE | ID: mdl-38563834
17.
The emerging role of PI3K inhibitors for solid tumour treatment and beyond.
Br J Cancer
; 128(12): 2150-2162, 2023 06.
Article
in English
| MEDLINE | ID: mdl-36914722
18.
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Br J Cancer
; 128(1): 30-41, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36335217
19.
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens' Targetability.
Oncologist
; 28(11): 944-960, 2023 Nov 02.
Article
in English
| MEDLINE | ID: mdl-37665782
20.
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies.
Oncologist
; 28(7): 565-574, 2023 07 05.
Article
in English
| MEDLINE | ID: mdl-37210568